FDA Announces Launch of Generative AI Tool
The FDA has announced the launch of Elsa, “a generative artificial intelligence (AI) tool designed to help employees—from scientific reviewers to investigators—work more efficiently.”
FDA Commissioner Marty Makary touted a “very successful pilot program with FDA’s scientific reviewers” surrounding Elsa. The tool was “built within a high-security GovCloud environment” and “offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff.”
The agency says it is “already using Elsa to accelerate clinical protocol reviews, shorten the time needed for scientific evaluations, and identify high-priority inspection targets.” It is designed to “assist with reading, writing, and summarizing. It can summarize adverse events to support safety profile assessments, perform faster label comparisons, and generate code to help develop databases for nonclinical applications.”
FDA also has “plans to integrate more AI in different processes, such as data processing and generative-AI functions to further support the FDA’s mission.”
HPN previously reported on the FDA’s drive to push AI across all of its centers by the end of June, as well as reactions around the industry to the technology.
About the Author
Matt MacKenzieMatt MacKenzie
Associate Editor
Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care.
Related
ai_3
medical_ai